Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21157397 | 0.89 | KMT2A (0.39) | ALDH1A1KMT2AMEN1MAPK1HDAC4 | |
| SCHEMBL21157406 | 0.89 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1MAPK1HDAC4 | |
| SCHEMBL21157400 | 0.86 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1MAPK1HDAC4 | |
| SCHEMBL21746351 | 0.84 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1MAPK1HDAC4 | |
| SCHEMBL31528782 | 0.83 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1MAPK1HDAC4 | |
| SCHEMBL14899591 | 0.78 | DPP4 (0.36) | ALDH1A1KMT2AMEN1MAPK1HDAC4 | |
| SCHEMBL21157404 | 0.78 | KMT2A (0.34) | KMT2AMEN1MAPK1HDAC4HDAC1 | |
| SCHEMBL21156214 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1MAPK1HDAC4 | |
| SCHEMBL25836420 | 0.77 | ELANE (0.39) | DPP8DPP9DPP4FAPDPP7 | |
| SCHEMBL17598284 | 0.77 | DPP4 (0.62) | DPP8DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090919-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | PITON THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090920-A1 | COMPOSITIONS AND METHODS FOR TREATING DYSFUNCTION OF GLUCOSE METABOLISM AND/OR REGULATION | PITON THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | AVACTA LIFE SCIENCES, LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | CD47, VCAM1, CD44 | ALDH1A1 1284/4885KMT2A 2451/4885MEN1 3526/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | ALDH1A1 2403/4885KMT2A 1719/4885MEN1 2512/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | ALDH1A1 1198/4885KMT2A 3963/4885MEN1 3338/4885 |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | VIP, PREP, PRAP1 | ALDH1A1 4348/4885KMT2A 3623/4885MEN1 1707/4885 |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | ALDH1A1 2261/4885KMT2A 1488/4885MEN1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.